Search
Boehringer_Ingelheim_Corporate_Factsheet.pdf
Boehringer_Ingelheim_Kurzbericht_2016.pdf
Boehringer_Ingelheim_Summary_Report_2016.pdf
Boehringer_Ingelheim_Annual_Report_2016.pdf
Boehringer_Ingelheim_Unternehmensbericht_2016.pdf
Boehringer_Ingelheim_Company_Profile_2017.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf
FSA-Transparenzbericht Boehringer Ingelheim 2016.pdf
Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
Partnering with Boehringer Ingelheim HP OCTOBER 2024 CORP.pdf
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Use of data: "A game changer for our industry"
Data is a game changer for the pharmaceutical industry and will shape our business. Listen to our podcast.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Facts about the INPULSIS™ trials
Purpose Hero Video
Begin a career with purpose and explore careers at Boehringer Ingelheim.
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Facts About IPF
IPF is a debilitating and fatal lung disease.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
weBuy
Supplier Information: WeBuy is a key initiative in order to have an integrated solution for the Source to Procure Process around the globe.
Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.